NCT01534715View on ClinicalTrials.gov

IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Lymphoma, Non-HodgkinChronic Lymphocytic Leukemia
Interventions
DRUG

IMGN529

Trial Locations (7)

10021

Memorial Sloan-Kettering Cancer Center, New York

37203

Sarah Cannon Research Institute, Nashville

43210

Ohio State University, Columbus

53226

Medical College of Wisconsin, Milwaukee

78229

CTRC at UTHSCSA, San Antonio

02215

Dana Farber Cancer Institute, Boston

CH-5800

Oncology Institute of Southern Switzerland, Bellinzona

Sponsors

Lead Sponsor

ImmunoGen, Inc.
All Listed Sponsors
lead

ImmunoGen, Inc.

INDUSTRY

NCT01534715 - IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter